A research group at the University of Salamanca works on the development and validation of an aerosol containing nanoparticles vectorized to treat human lung carcinoma.

The project was awarded in the XVIII call for research grants of the Ramón Areces Foundation. This project aims to develop and validate in vivo an aerosol consisting of vectorized particles capable of locally and selectively treating human non-small cell lung cancer (NSCLC). For this, nanoparticles (200 nm) consisting of two types of biopolymers, levan and alginate will be prepared. Both will be functionalized on the surface with cisplatin and EGF (epithelial growth factor). In addition, to check for potential synergy in treatment, cisplatin and paclitaxel (PTX) will be combined in the same nanoparticle.

This methodology will allow comparing the efficacy of two types of biodegradable polymers as vectors of the same size (approximately 200 nm). The kinetics of drug release in both types of particles will be studied.

Posted by Juan M. Corchado

Catedrático en el Área de Ciencias de la Computación e Inteligencia Artificial de la Universidad de Salamanca. Director del Grupo de Investigación BISITE // Full Professor in Area of Computer Science and Artificial Intelligence at University of Salamanca. Director of the BISITE Research Group

Thanks for your comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.